PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

DiosCURE to develop highly specific single-chain antibodies against SARS-CoV-2

Lead candidates described in Science publication

DiosCURE to develop highly specific single-chain antibodies against SARS-CoV-2
2021-01-12
(Press-News.org) Core technology includes promising bivalent single-domain antibodies simultaneously targeting two surface structures of the viral spike protein. Lead candidates DIOS-202 and DIOS-203 are engineered for high potency and their potential to avoid the emergence of escape mutants. DIOS-202 and DIOS-203 entered into accelerated development to initiate clinical studies later this year.

BONN, Germany, January 12, 2021 - DiosCURE SE announced a publication in Science describing its core technology of multivalent single-chain antibodies with a unique molecular mode-of-action to inactivate SARS-CoV-2 virions. An international team led by scientists at the University of Bonn developed and characterized the lead candidates, which are exclusively licensed by DiosCURE.

"This global pandemic requires an arsenal of therapeutic and preventative tools and our lead candidates will allow us to contribute to what will be an ongoing battle," stated Klaus Wilgenbus, Chief Executive Officer at DiosCURE. "DiosCURE was established with the goal of developing novel, best-in-class immunotherapies to protect a significant population which will remain at risk, including exposed healthcare workers, immunocompromised patients, non-responders to vaccines and patients experiencing post-acute COVID-19 syndrome. The data now published provides a solid foundation to continue our development efforts with the goal of entering the clinic later this year."

The company's lead candidates, DIOS-202 and DIOS-203, are synergistic combinations of single-domain antibodies derived from camelid heavy chain-only antibodies. These next-generation immunotherapies against SARS-CoV-2 were designed based on detailed structural information of the antibodies' interaction with its viral target protein and result from functional and evolutionary experiments. The discovery and promising early preclinical data were published in an article in Science entitled "Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape" on January 12, 2021. The study details the identification of DiosCURE's lead candidates out of millions of potential structures, as well as the rational design of multivalent constructs, which increased neutralizing activity more than 100-fold. Preclinical studies demonstrated that DIOS-202 and DIOS-203 selectively target two distinct epitopes of the SARS-CoV-2 spike protein at once, which largely prevents the emergence of escape mutants. The dual targeting induces the premature activation of the fusion machinery, rendering the virions non-infectious. These discoveries were accomplished through a collaborative effort of research groups at the University Hospital of the University of Bonn (led by the Institute of Innate Immunity and the Core Facility Nanobodies), The Scripps Research Institute and the Karolinska Institutet.

The lead candidates are expected to be highly efficacious, well-tolerated, cost-efficient in production and are amenable to a wide range of clinical applications. As immunotherapies, DIOS-202 and DIOS-203 are suitable as prophylactic and to treat infected patients to avoid severe COVID-19 disease.

"The structure-based multivalent single-chain antibodies we discovered have strong potential for clinical applications. This is owed to their highly potent neutralizing activity and in-built protection from the rapid emergence of escape mutants. The emergence of SARS-CoV-2 escape mutants will remain an ongoing challenge in this pandemic, and novel therapies are urgently needed to address this problem," stated Eicke Latz, Director of the Institute of Innate Immunity at the University of Bonn, co-founder and Board member of DiosCURE. "Our understanding of the short- and long-term consequences of SARS-CoV-2 is rapidly evolving, and rational therapeutics targeting the virus are needed to curb the potentially devastating consequences of COVID-19."

INFORMATION:

About DiosCURE DiosCURE is developing next-generation immunotherapies focused on a novel approach against SARS-CoV-2. The Company's proprietary bi- and trivalent variable domains of heavy chain-only antibodies (VHHs) are synergistic combinations of single-domain antibodies, constructed following structural information and optimized for potency as well as their potential to avoid the emergence of escape mutants. DiosCURE designed lead candidates that target two different epitopes of the SARS-CoV-2 spike protein with the potential to be highly efficacious, well-tolerated and manufactured at a large-scale standardized process. To learn more about our company, please visit http://www.DiosCURE.com

DiosCURE Contacts: Klaus Wilgenbus, M.D.
Chief Executive Officer
info@DiosCURE.com

Media Contacts: Trophic Communications
Eva Mulder or Sophia Hergenhan, Ph.D.
DiosCURE@trophic.eu
+49 89 238 877 30


[Attachments] See images for this press release:
DiosCURE to develop highly specific single-chain antibodies against SARS-CoV-2

ELSE PRESS RELEASES FROM THIS DATE:

Healthcare Nutrition Council leads the way on medical food discussions

Healthcare Nutrition Council leads the way on medical food discussions
2021-01-12
While most people are able to eat a normal diet, many of those managing distinct nutritional requirements related to a disease or health condition rely on medical foods. Medical foods help patients meet their nutritional needs, often improving nutritional and health outcomes and quality of life. A recent publication in Current Developments in Nutrition, titled "Medical Foods: Science, Regulation, and Practical Aspects. Summary of a Workshop," shares the historical and regulatory context of medical foods and perspectives on their role in the future. Medical foods help patients manage their nutritional needs, yet it can be very difficult for patients to have access to them. In August 2019, the Healthcare Nutrition Council (HNC), in partnership with the American Society ...

Another common cold virus? Modeling SARS-CoV-2's progress through the ages

Another common cold virus? Modeling SARS-CoV-2s progress through the ages
2021-01-12
What is the endgame for SARS-CoV-2, the virus that is causing worldwide devastation? If it becomes endemic -- circulating in the general population -- and most people are exposed in childhood, SARS-CoV-2 may join the ranks of mild cold-causing coronaviruses that currently circulate in humans, according to a model developed by Emory and Penn State scientists. The model, published January 12 in Science, draws upon studies of the four common cold coronaviruses and SARS-CoV-1. For those viruses, the term "herd immunity" is incomplete and possibly misleading, says ...

New promising antibodies against SARS-CoV-2

New promising antibodies against SARS-CoV-2
2021-01-12
Antibodies are an important weapon in the immune system's defense against infections. They bind to the surface structures of bacteria or viruses and prevent their replication. One strategy in the fight against disease is therefore to produce effective antibodies in large quantities and inject them into the patients. The outgoing US President Donald Trump probably owes his rapid recovery to this method. However, the antibodies used to treat him have a complex structure, do not penetrate very deeply into the tissue and may cause unwanted complications. Moreover, producing antibodies is difficult and time-consuming. They are therefore probably not suitable for widespread use. Mass production in yeast or bacteria "We focus on another group of molecules, the nanobodies," ...

New small antibodies show promising effects against COVID-19 infection

2021-01-12
Researchers at Karolinska Institutet in Sweden have developed, in collaboration with researchers in Germany and the U.S., new small antibodies, also known as nanobodies, which prevent the SARS-CoV-2 coronavirus from entering human cells. The research study, published in Science, shows that a combined nanobody had a particularly good effect - even if the virus mutated. According to the researchers, the nanobodies have the potential to be developed into a treatment for COVID-19. Specific proteins, spike proteins, on the surface of the SARS-CoV-2 coronavirus help the virus infect host cells. Therefore, antibodies that block the spike proteins and prevent them from binding to the cell can be a way to stop infection. From the perspective ...

How will SARS-CoV-2 severity change in the next decade?

2021-01-12
What will the SARS-CoV-2 outbreak look like ten years from now as it passes from pandemic to endemic, maintained at a constant baseline level in populations without being fueled by outside infections? Data from four endemic human coronaviruses, which circulate globally and cause only mild symptoms, may hold some answers, say Jennie Lavine and colleagues. Their analysis of the immunological and epidemiological data for these viruses helped them develop a model to predict the trajectory of SARS-CoV-2 as it becomes endemic. Most importantly, the authors say, their model incorporates distinct components of immunological protection--susceptibility to reinfection, weakening of the disease after reinfection, and transmissibility of the virus after reinfection--that each wane differently. Lavine ...

Strategy tested in mice protects against SARS-CoV-2 & coronaviruses that represent human threats

2021-01-12
An immunization strategy tested in mice protects against infection from SARS-CoV-2, as well as from potentially emerging animal coronaviruses, researchers say. The approach could be "used as described or easily adapted" to provide defense against newly discovered zoonotic coronaviruses. In the last 20 years, three betacoronaviruses have caused devastating disease in humans. The global pandemic caused by the latest such virus, SARS-CoV-2, highlights the need to protect against other strains that could present a threat to humans, possibly through a pan-coronavirus vaccine. To support related efforts, ...

New taxonomy of non-skeletal rare disorders with impact on bone

2021-01-12
Thanks to major progress in the understanding and management of rare congenital diseases and syndromes, many patients with these rare disorders are now living longer lives. With this progress it has become apparent that many non-skeletal rare diseases have an impact on bone mass, bone quality and/or bone metabolism, with potentially severe repercussions for quality of life in adults. The new paper 'Bone fragility in patients affected by congenital diseases non skeletal in origin', published in Orphanet Journal of Rare Diseases by the International Osteoporosis Foundation (IOF) Skeletal Rare Diseases Working Group (SRDWG), provides ...

Turbulent dynamics in the human brain could revolutionize the understanding of its functionality

2021-01-12
Most people experience turbulence primarily from the experience of flying in an airplane. However, turbulence is a key feature of nature and is found everywhere, from rivers to galaxies. Turbulent-like dynamics are difficult to capture in a still image. However, Leonardo da Vinci did everything possible to identify the underlying order of the phenomenon, which he observed in eddy currents forming randomly in water. In fact, he was fascinated by trying to understand and describe the generating principles governing such complicated dynamics. This is so much ...

Artificial intelligence puts focus on the life of insects

Artificial intelligence puts focus on the life of insects
2021-01-12
Scientists are combining artificial intelligence and advanced computer technology with biological know how to identify insects with supernatural speed. This opens up new possibilities for describing unknown species and for tracking the life of insects across space and time Insects are the most diverse group of animals on Earth and only a small fraction of these have been found and formally described. In fact, there are so many species that discovering all of them in the near future is unlikely. This enormous diversity among insects also means that they have very different life histories and roles in the ecosystems. For ...

Study finds future too warm for baby sharks

Study finds future too warm for baby sharks
2021-01-12
A new study conducted at the New England Aquarium finds that as climate change causes the ocean to warm, baby sharks are born smaller, exhausted, undernourished, and into environments that are already difficult for them to survive in. In a recently published paper in the journal Scientific Reports, lead author Carolyn Wheeler, a Ph.D. candidate at the University of Massachusetts Boston and at the ARC Centre of Excellence for Coral Reef Studies at James Cook University, examined the effects of increased temperatures on the growth, development and physiological performance of epaulette ...

LAST 30 PRESS RELEASES:

Research reveals missed opportunities to save George Floyd’s life

HKUST discovers novel elastic alloy achieving 20x temperature change and 90% carnot efficiency in solid-state heat pumping

Early prediction of preterm birth in cell-free RNA may revolutionize prevention strategies

Largest phase 3 trial of novel treatment for hypertension shows promising results

European regulation needed to prevent the birth of children with inherited cancer-causing genetic mutation after sperm donation

Assembly instructions for enzymes

Rice geophysicist Ajo-Franklin wins Reginald Fessenden Award for pioneering work in fiber optic sensing

Research spotlight: New therapeutic approach stops glioblastoma from hijacking the immune system

‘Hopelessly attached’: Scientists discover new 2D material that sticks the landing

Flowers unfold with surprising precision, despite unruly genes

Research spotlight: Study provides a window into public perceptions about technological treatment options for brain conditions

Sound insulation tiles at school help calm crying children #ASA188

More young adults than ever take HIV-prevention medication, but gaps remain

Why are some rocks on the moon highly magnetic? MIT scientists may have an answer

Unique chemistry discovered in critical lithium deposits

Numerical simulations reveal the origin of barred olivine crystals in early solar system

Daytime boosts immunity, scientists find

How marine plankton adapts to a changing world

Charge radius of Helium-3 measured with unprecedented precision

Oral microbiota transmission partially mediates depression and anxiety in newlywed couples

First vascularized model of stem cell islet cells

US excess deaths continued to rise even after the COVID-19 pandemic

Excess US deaths before, during, and after the COVID-19 pandemic

Millions of HealthCare.gov participants face coverage loss due to burdensome reenrollment policies, according to new research

Study: DNA test detects three times more lung pathogens than traditional methods

Modulation of antiviral response in fungi via RNA editing

Global, regional, and national burden of nontraumatic subarachnoid hemorrhage

Earliest use of psychoactive and medicinal plant ‘harmal’ identified in Iron Age Arabia

Nano-scale biosensor lets scientists monitor molecules in real time

Study shows how El Niño and La Niña climate swings threaten mangroves worldwide

[Press-News.org] DiosCURE to develop highly specific single-chain antibodies against SARS-CoV-2
Lead candidates described in Science publication